XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of weighted-average assumptions used to value options as of their grant date The weighted-average assumptions used to value options as of their grant date were as follows:
 Year Ended
December 31,
 20202019
Risk-free interest rate0.21 %1.91 %
Expected volatility44.0 %36.9 %
Expected life (in years)4.294.27
Dividend yield%%
Schedule of share-based compensation, stock options, activity
The changes in outstanding stock options for the year ended December 31, 2020 and 2019 are as follows:
 
Number of OptionsWeighted Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in Years)
Aggregate Intrinsic
Value
Outstanding at December 31, 2019
1,624 $9.86 
Granted654 $8.12 
Exercised(110)$8.02 
Expired, canceled or forfeited(134)$12.14 
Outstanding at December 31, 2020
2,034 $9.25 3.21$4,288 
Exercisable at December 31, 2020
611 $9.83 2.19$939 
Options vested or expected to vest at December 31, 2020
2,034 $9.25 3.21$4,288 
Number of OptionsWeighted Average
Exercise Price
Weighted Average
Remaining
Contractual Life
(in Years)
Aggregate Intrinsic
Value
Outstanding at December 31, 2018
1,276 $10.28 
Granted630 $9.48 
Exercised(37)$7.89 
Expired, canceled or forfeited(245)$11.35 
Outstanding at December 31, 2019
1,624 $9.86 3.25$2,325 
Exercisable at December 31, 2019
440 $10.26 2.07$572 
Options vested or expected to vest at December 31, 2019
1,624 $9.86 3.25$2,325 
Schedule of share-based compensation, restricted stock and restricted stock units activity
Restricted stock activity under the 2006 Plan and the 2016 Plan for 2020 is as follows:
 
Number of
Shares
Weighted-
average
grant date
fair value
Outstanding at December 31, 2019, unvested
498 $9.51 
Granted317 8.19 
Vested(252)9.18 
Forfeited(7)10.00 
Outstanding at December 31, 2020, unvested
556 $8.90 
Schedule of share-based compensation, activity
The following presents stock-based compensation expense, including expense for the ESPP, in the Company's consolidated statements of operations for the years ended December 31, 2020 and 2019.
20202019
Cost of product sales$165 $240 
Cost of service sales— — 
Research and development593 815 
Sales, marketing and support682 867 
General and administrative2,022 2,237 
$3,462 $4,159 
Schedule of Accumulated Other Comprehensive Income (Loss) The components of the Company’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive income (loss).
     
Foreign Currency TranslationInterest Rate SwapsTotal Accumulated Other Comprehensive Loss
Balance, December 31, 2018
$(14,720)$(11)$(14,731)
Other comprehensive income before reclassifications470 473 
Amounts reclassified from AOCI11,483 11,491 
Net other comprehensive income11,953 11 11,964 
Balance, December 31, 2019
(2,767) (2,767)
Other comprehensive loss(465)— (465)
Net other comprehensive loss(465)— (465)
Balance, December 31, 2020
$(3,232)$ $(3,232)